Explore

Research Explores Interplay of Nutrition, Metabolism, Sleep, and Circadian Rhythms in Health and Disease

Research Explores Interplay of Nutrition, Metabolism, Sleep, and Circadian Rhythms in Health and Disease

A new research topic, "Nourishing the Clock: Metabolic and Nutritional Influences on Sleep and Circadian Rhythms," aims to deepen the understanding of how diet, metabolism, sleep, and circadian rhythms are interconnected biological systems that impact health. This initiative will investigate how the timing and composition of food intake affect circadian regulation, metabolic pathways, sleep outcomes, and physiological resilience. Conversely, it will also examine how insufficient or mistimed sleep and circadian disruption, often associated with shift work, irregular schedules, and social jet lag, can alter appetite, dietary behavior, and metabolic health. The research seeks to clarify the mechanisms linking feeding-fasting cycles with central and peripheral clock systems and to identify intervention strategies for prevention and treatment. Studies have already highlighted associations between circadian disruption, altered dietary patterns, obesity, diabetes, and sleep disorders, but further research is need...

Zealand Pharma Establishes New Research Hub in Cambridge, Massachusetts

Zealand Pharma Establishes New Research Hub in Cambridge, Massachusetts

Zealand Pharma Establishes New Research Hub in Cambridge, Massachusetts

University of Geneva Researchers Uncover How Biological Clock Regulates Wakefulness in Fruit Flies

University of Geneva Researchers Uncover How Biological Clock Regulates Wakefulness in Fruit Flies

Researchers at the University of Geneva (UNIGE), led by Emi Nagoshi's laboratory, have made significant strides in understanding how the biological clock regulates phases of wakefulness. Using fruit flies as a model, the team identified specific neural circuits that transmit information from the circadian clock to brain regions involved in sleep and wakefulness. The study, published in 'Current Biology,' details how clock neurons inhibit dopaminergic neurons, which in turn stimulate neurons in the mushroom body—a brain region crucial for learning, memory, and sleep regulation. This inhibition by clock neurons reduces the wake-promoting signal, while its release allows dopaminergic neurons to more strongly stimulate the mushroom body, thereby promoting wakefulness. This mechanism reveals how the biological clock communicates time-of-day information to influence brain circuits, highlighting the central role of dopamine in this process.

Avner Schlessinger Appointed Chair of UNC Department of Pharmacology

Avner Schlessinger Appointed Chair of UNC Department of Pharmacology

Avner Schlessinger, PhD, has been named the new chair of the UNC Department of Pharmacology at the University of North Carolina at Chapel Hill. Dr. Schlessinger is slated to begin his tenure in February 2027. He will succeed Henrik Dohlman, PhD, who will step down from the chair position in February but will remain a faculty member within the department. Dr. Schlessinger is currently the director of the AI Small Molecule Drug Discovery Center and the Dr. Amy and James Elster Professor of Molecular Biology and a professor of pharmacological sciences at the Icahn School of Medicine at Mount Sinai. His research focuses on integrating computational chemistry, artificial intelligence, structural biology, and experimental pharmacology to improve and automate the structure-based drug discovery process. He holds a B.Sc. in chemistry and biology from Tel Aviv University and a PhD in biochemistry and molecular biophysics from Columbia University.

AI Scientist Autonomously Generates and Validates New Biological Discoveries

AI Scientist Autonomously Generates and Validates New Biological Discoveries

Researchers from Chalmers University of Technology in Sweden have developed an 'AI scientist' capable of autonomously generating scientific hypotheses, designing experiments, and interpreting results. This closed-loop AI laboratory integrates large language models, automated reasoning, and laboratory automation. The system was tested using the common baker's yeast, Saccharomyces cerevisiae, as its subject. The AI was fed scientific knowledge about yeast genomes, metabolism, and existing research. From this data, it identified promising biological questions, proposed experiments to answer them, and evaluated the outcomes to refine its hypotheses for subsequent experiments. This development demonstrates the AI's ability to not merely assist in decision-making but to actively generate new scientific knowledge through experimentation.

Intermittent Fasting Explained: Metabolic Benefits and Weight Management

Intermittent Fasting Explained: Metabolic Benefits and Weight Management

Intermittent Fasting Explained: Metabolic Benefits and Weight Management

Sleep Expert Emphasizes Circadian Rhythm and Lifestyle for Improved Sleep Quality

Sleep Expert Emphasizes Circadian Rhythm and Lifestyle for Improved Sleep Quality

Sleep Expert Emphasizes Circadian Rhythm and Lifestyle for Improved Sleep Quality

Profluent Partners with BioMarin to Design Novel Medicines Using AI for Genetically Defined Conditions

Profluent Partners with BioMarin to Design Novel Medicines Using AI for Genetically Defined Conditions

Profluent, an AI lab specializing in biology, has announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies. This partnership aims to advance next-generation candidates for genetically defined conditions. Profluent will leverage its proprietary protein language models, which utilize the Profluent Protein Atlas—the world's largest protein sequence dataset with over 115 billion unique sequences—to generate and optimize enzyme candidates. BioMarin will then screen these AI-designed proteins to identify potential drug candidates with desired activity and stability profiles for further evaluation and preclinical testing. This collaboration combines Profluent's advanced AI models for de novo protein design with BioMarin's extensive expertise in enzyme replacement therapies.

Tempus AI Seeks Computational Biologist for Pharma R in Boston

Tempus AI Seeks Computational Biologist for Pharma R in Boston

Tempus AI Seeks Computational Biologist for Pharma R in Boston

Calorie Calculator Provides Estimates for Weight Management Based on Activity Levels

Calorie Calculator Provides Estimates for Weight Management Based on Activity Levels

Calorie Calculator Provides Estimates for Weight Management Based on Activity Levels

University of Liverpool Study Finds Non-Nutritive Sweetened Beverages Equivalent to Water for Long-Term Weight Management

University of Liverpool Study Finds Non-Nutritive Sweetened Beverages Equivalent to Water for Long-Term Weight Management

Researchers at the University of Liverpool have completed the longest and most comprehensive randomized controlled trial on non-nutritive sweetened (NNS) soft drinks. The 104-week clinical trial, published in the British Journal of Nutrition, indicates that NNS beverages are equivalent to water for long-term weight management. The study, funded by the American Beverage Association, involved 493 adults who were overweight or obese and participated in a structured behavioral weight management program. Participants were randomized to consume either water or commercially available diet beverages daily, with sweeteners like aspartame, acesulfame potassium, and sucralose provided within established European Food Safety Authority (EFSA) safety thresholds. Key findings include equivalent weight loss between NNS beverage and water groups at 104 weeks, sustained weight reduction over two years, and improvements in waist and hip circumference, body composition, and several metabolic biomarkers in both groups. The stu...

U.S. Study Reveals High Nutritional Deficiency Rates in Children on GLP-1 Medicines for Diabetes and Obesity

U.S. Study Reveals High Nutritional Deficiency Rates in Children on GLP-1 Medicines for Diabetes and Obesity

A recent U.S. study has found that approximately one in six children and teenagers (16.8%) prescribed GLP-1 receptor agonists for type 2 diabetes, severe obesity, or related metabolic conditions developed a nutritional deficiency or related complication within a year of starting treatment. The study analyzed insurance records of 2,031 young individuals aged 10 to 17 who began GLP-1 treatment between 2017 and 2022. Before starting the medication, none of these participants had a recorded nutritional deficiency. Within six months, 10.2% had been diagnosed with at least one deficiency, a figure that rose to 16.8% by the one-year mark. Vitamin D deficiency was the most common issue, affecting 12.4% of the group, followed by nutritional anemia (1.6%), iron-deficiency anemia (1.4%), and muscle loss (0.8%). The research also highlighted a significant gap in nutritional support, with only 5.8% receiving a nutrition consultation within 30 days of starting treatment, and only 23.3% by six months.